Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Cardiology
•
Preventive Cardiology
What is a reasonable way to treat statin-induced myalgia and what statin substitute would you consider using in the event the myalgia is not resolved?
Answer from: at Community Practice
Qunol co administration Vytorin - lower doses PCSK9
Comments
at Valley Heart Institute Of Doctors Medical Center
Opportunities with pcsk9 monoclonal antibodies or ...
11574
Sign in or Register to read more
21557
Related Questions
What is your approach to determining the safety, appropriateness, and timing of SPECT or PET MPI in patients admitted with NSTEMI and who remain chest pain-free and hemodynamically stable?
What do you make of the results of the recent phase 2 RCT on Zerlasiran in terms of effectiveness at reducing lipoprotein (a) levels and the timing for when this will become readily available for patients who may benefit the most from it?
What is a reasonable approach to coronary calcification that is incidentally found on CT in a patient who does not have symptoms suggestive of angina?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
Is it worth getting a calcium score on a patient who is already on statin therapy?
For women with known autoimmune diseases, how do you approach ASCVD risk stratification when deciding to start a statin or aspirin for primary prevention?
Should low-intensity statins be favored to minimize the risk of diabetes onset while still offering cardiovascular benefit for patients with prediabetes where a statin is indicated?
Is there a role for colchicine in the management of patients after a myocardial infarction given the conflicting results of the COLCOT trial, which found a significant reduction in subsequent cardiovascular events, and the CLEAR SYNERGY (OASIS-9) trial, which did not find a significant benefit?
What are your top takeaways from ACC 2024?
Are there any ongoing clinical trials related to endothelial dysfunction and accelerated or premature CAD that patients might be able to enroll in nationwide?
Opportunities with pcsk9 monoclonal antibodies or ...